Drug Trial Radar · NCT00242801
Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study
Last checked: Nov 19, 2026Latest source record: Apr 23, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,692
Actual
Start
Jul 2003
Primary completion
Not stated
Study completion Apr 2005
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 21, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being carried out to see if adding ZD1839 to other standard supportive care is more effective than standard supportive care alone for the treatment of patients with NSCLC whose disease has recurred after previous chemotherapy treatment.
Conditions
- NSCLC
Interventions
GefitinibDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary objective of this study is to compare overall survival for ZD1839 plus best supportive care versus placebo plus best supportive care
Locations
211 sites in 32 countries. Site status is shown where the registry gives one.
Research Site
Bahía Blanca, Argentina
Research Site
Buenos Aires, Argentina
Research Site
La Plata, Argentina
Research Site
Mar del Plata, Argentina
Research Site
Rosario, Argentina
Research Site
Santa Fe, Argentina
Research Site
Capital Federal, Buenos Aires, Argentina
Research Site
Woodville South, Australia
Research Site
Concord, New South Wales, Australia
Research Site
Potts Point, New South Wales, Australia
Research Site
St Leonards, New South Wales, Australia
Research Site
Chermside, Queensland, Australia
Research Site
South Brisbane, Queensland, Australia
Research Site
Ashford, South Australia, Australia
Research Site
Woodville, South Australia, Australia
Research Site
Melbourne, Victoria, Australia
Research Site
Parkville, Victoria, Australia
Research Site
Prahran, Victoria, Australia
Research Site
Wodonga, Victoria, Australia
Research Site
Fortaleza, Ceará, Brazil
Research Site
Belo Horizonte, Minas Gerais, Brazil
Research Site
Rio de Janeiro, Rio de Janeiro, Brazil
Research Site
Porto Alegre, Rio Grande do Sul, Brazil
Research Site
São Paulo, São Paulo, Brazil
Research Site
Sorocaba, São Paulo, Brazil
Research Site
Pleven, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Stara Zagora, Bulgaria
Research Site
Varna, Bulgaria
Research Site
Veliko Tarnovo, Bulgaria
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Monoton, New Brunswick, Canada
Research Site
Greater Sudbury, Ontario, Canada
Research Site
Mississauga, Ontario, Canada
Research Site
Newmarket, Ontario, Canada
Research Site
Saint Catherines, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
York, Ontario, Canada
Showing 40 of 211 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.